The Legumain Protease‐Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity
- 10 December 2010
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 6 (1), 54-59
- https://doi.org/10.1002/cmdc.201000478
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- An efficient chemical approach to bispecific antibodies and antibodies of high valencyBioorganic & Medicinal Chemistry Letters, 2009
- Multiple catalytic aldolase antibodies suitable for chemical programmingBioorganic & Medicinal Chemistry Letters, 2009
- Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approachTetrahedron Letters, 2009
- Instant immunity through chemically programmable vaccination and covalent self-assemblyProceedings of the National Academy of Sciences of the United States of America, 2009
- Emerging roles of proteases in tumour suppressionNature Reviews Cancer, 2007
- Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activationProceedings of the National Academy of Sciences of the United States of America, 2007
- Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cellsFEBS Letters, 2007
- MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma researchBreast Cancer Research and Treatment, 2006
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJCI Insight, 2006
- Breaking the one antibody–one target axiomProceedings of the National Academy of Sciences of the United States of America, 2006